

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Synribo (omacetaxine mepesuccinate)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Synribo (omacetaxine mepesuccinate)

APPROVAL CRITERIA

Requests for Synribo (omacetaxine mepesuccinate) may be approved if the following criteria are met:

- I. Individual has a diagnosis of chronic or accelerated phase chronic myeloid leukemia (CML); **AND**
- II. Individual has resistance and/or intolerance to TWO or more tyrosine kinase inhibitors (TKI);

OR

- III. Individual has a diagnosis of CML and is using as monotherapy (NCCN 2A); **AND**
 - A. Individual is receiving for post-allogenic stem cell transplant follow-up therapy with molecular relapse (BCR-ABL1 transcript) following complete cytogenetic response (CCyR); **OR**
 - B. Individual is receiving for post-allogenic stem cell transplant follow-up therapy with relapse or those who are not in CCyR; **OR**
 - C. Individual has T315I mutation positive disease.

Note:

Tyrosine kinase inhibitors include Gleevec (imatinib), Tasigna (dasatinib), Sprycel (nilotinib), Bosulif (bosutinib), Iclusig (ponatinib)

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

CRX-ALL-0522-20

PAGE 1 of 2 02/27/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: September 27, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on September 27, 2019.
 - a. Chronic Myeloid Leukemia. V2.2020. September 25, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.